145 related articles for article (PubMed ID: 33231110)
1. Efficacy and Tolerability of Rufinamide in Epileptic Children Younger Than 4 Years.
Tanritanir A; Wang X; Loddenkemper T
J Child Neurol; 2021 Mar; 36(4):281-287. PubMed ID: 33231110
[TBL] [Abstract][Full Text] [Related]
2. Rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy: A retrospective single center study.
Oesch G; Bozarth XL
Epilepsy Res; 2020 Dec; 168():106211. PubMed ID: 31575436
[TBL] [Abstract][Full Text] [Related]
3. Rufinamide add-on therapy for drug-resistant epilepsy.
Panebianco M; Prabhakar H; Marson AG
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD011772. PubMed ID: 33179247
[TBL] [Abstract][Full Text] [Related]
4. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience.
Thome-Souza S; Kadish NE; Ramgopal S; Sánchez Fernández I; Bergin AM; Bolton J; Harini C; Libenson M; Olson H; Peters J; Poduri A; Rotenberg A; Takeoka M; Kothare SV; Kapur K; Bourgeois BF; Loddenkemper T
Epilepsia; 2014 Aug; 55(8):1235-44. PubMed ID: 25070475
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies.
Grosso S; Coppola G; Dontin SD; Gobbi G; Pruna D; Accorsi P; Verrotti A; Parisi P; Balestri P
Eur J Paediatr Neurol; 2014 Sep; 18(5):641-5. PubMed ID: 24912730
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.
Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rufinamide in childhood refractory epilepsy.
Yıldız EP; Hızlı Z; Bektaş G; Ulak-Özkan M; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
Turk J Pediatr; 2018; 60(3):238-243. PubMed ID: 30511535
[TBL] [Abstract][Full Text] [Related]
8. Rufinamide for refractory epilepsy in a pediatric and young adult population.
Joseph JR; Schultz RJ; Wilfong AA
Epilepsy Res; 2011 Jan; 93(1):87-9. PubMed ID: 21111576
[TBL] [Abstract][Full Text] [Related]
9. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy.
Kluger G; Haberlandt E; Kurlemann G; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
Epilepsy Behav; 2010 Apr; 17(4):546-8. PubMed ID: 20185372
[TBL] [Abstract][Full Text] [Related]
10. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders.
Cusmai R; Verrotti A; Moavero R; Curatolo P; Battaglia D; Matricardi S; Spalice A; Vigevano F; Pruna D; Parisi P; D'Aniello A; Di Gennaro G; Coppola G
Epilepsy Res; 2014 Mar; 108(3):542-6. PubMed ID: 24548548
[TBL] [Abstract][Full Text] [Related]
11. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.
Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Verrotti A; D'Aniello A; Mangano S; Balestri A; Curatolo P; Pascotto A
Eur J Neurol; 2011 Feb; 18(2):246-251. PubMed ID: 20666837
[TBL] [Abstract][Full Text] [Related]
12. Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy.
Jackson MC; Jafarpour S; Klehm J; Thome-Souza S; Coughlin F; Kapur K; Loddenkemper T
Epilepsia; 2017 Sep; 58(9):1575-1585. PubMed ID: 28691157
[TBL] [Abstract][Full Text] [Related]
13. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome.
Kim SH; Kang HC; Lee JS; Kim HD
Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea.
Lee EH; Yum MS; Ko TS
Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943
[TBL] [Abstract][Full Text] [Related]
15. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M
Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364
[TBL] [Abstract][Full Text] [Related]
16. Experience with rufinamide in a pediatric population: a single center's experience.
Vendrame M; Loddenkemper T; Gooty VD; Takeoka M; Rotenberg A; Bergin AM; Eksioglu YZ; Poduri A; Duffy FH; Libenson M; Bourgeois BF; Kothare SV
Pediatr Neurol; 2010 Sep; 43(3):155-8. PubMed ID: 20691934
[TBL] [Abstract][Full Text] [Related]
17. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.
Pålhagen S; Canger R; Henriksen O; van Parys JA; Rivière ME; Karolchyk MA
Epilepsy Res; 2001 Feb; 43(2):115-24. PubMed ID: 11164700
[TBL] [Abstract][Full Text] [Related]
18. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.
Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Capovilla G; Verrotti A; Mangano S; Balestri A; Curatolo P; Pascotto A
Seizure; 2010 Nov; 19(9):587-91. PubMed ID: 20888268
[TBL] [Abstract][Full Text] [Related]
19. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.
Coppola G; Besag F; Cusmai R; Dulac O; Kluger G; Moavero R; Nabbout R; Nikanorova M; Pisani F; Verrotti A; von Stülpnagel C; Curatolo P
Eur J Paediatr Neurol; 2014 Nov; 18(6):685-90. PubMed ID: 24929673
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy.
Kim SH; Lee JH; Ryu HW; Lim BC; Chae JH; Choi JE; Hwang YS; Kim KJ
Epileptic Disord; 2013 Mar; 15(1):49-54. PubMed ID: 23531645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
